HANXBIO-B spends HK$1.32 million to buy back 45,700 H-shares, trimming issued float by 0.034%

Bulletin Express07-13

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return dated 13 July 2026, confirming an on-market repurchase of 45,700 H-shares on the Hong Kong Stock Exchange.

The transaction, executed on 13 July 2026 under the company’s existing buyback mandate, was completed at prices ranging from HK$28.48 to HK$30.00 per share, with a volume-weighted average cost of HK$28.98. Total consideration amounted to HK$1.32 million.

Following the repurchase, the number of issued shares (excluding treasury shares) fell by 0.034% to 134.25 million, while treasury shares rose to 1.97 million. The company’s total issued share capital remained unchanged at 136.22 million shares.

The buyback forms part of the mandate approved on 24 June 2026, which authorises the repurchase of up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 446,100 shares, equivalent to 0.33% of the company’s issued share base at the mandate date. A moratorium on new share issues or treasury-share sales is in effect until 12 August 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146338242?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-13 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146338242","market":"hk","top_or_hot":-1,"title":"HANXBIO-B spends HK$1.32 million to buy back 45,700 H-shares, trimming issued float by 0.034%","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return dated 13 July 2026, confirming an on-market repurchase of 45,700 H-shares on the Hong Kong Stock Exchange.</p>\n<p>The transaction, executed on 13 July 2026 under the company’s existing buyback mandate, was completed at prices ranging from HK$28.48 to HK$30.00 per share, with a volume-weighted average cost of HK$28.98. Total consideration amounted to HK$1.32 million.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) fell by 0.034% to 134.25 million, while treasury shares rose to 1.97 million. The company’s total issued share capital remained unchanged at 136.22 million shares.</p>\n<p>The buyback forms part of the mandate approved on 24 June 2026, which authorises the repurchase of up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 446,100 shares, equivalent to 0.33% of the company’s issued share base at the mandate date. A moratorium on new share issues or treasury-share sales is in effect until 12 August 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B spends HK$1.32 million to buy back 45,700 H-shares, trimming issued float by 0.034%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B spends HK$1.32 million to buy back 45,700 H-shares, trimming issued float by 0.034%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-13 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return dated 13 July 2026, confirming an on-market repurchase of 45,700 H-shares on the Hong Kong Stock Exchange.</p>\n<p>The transaction, executed on 13 July 2026 under the company’s existing buyback mandate, was completed at prices ranging from HK$28.48 to HK$30.00 per share, with a volume-weighted average cost of HK$28.98. Total consideration amounted to HK$1.32 million.</p>\n<p>Following the repurchase, the number of issued shares (excluding treasury shares) fell by 0.034% to 134.25 million, while treasury shares rose to 1.97 million. The company’s total issued share capital remained unchanged at 136.22 million shares.</p>\n<p>The buyback forms part of the mandate approved on 24 June 2026, which authorises the repurchase of up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 446,100 shares, equivalent to 0.33% of the company’s issued share base at the mandate date. A moratorium on new share issues or treasury-share sales is in effect until 12 August 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1146338242","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146338242","pubTimestamp":1783940803,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return dated 13 July 2026, confirming an on-market repurchase of 45,700 H-shares on the Hong Kong Stock Exchange....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉生生物斥资132万港元回购4.57万股H股，削减已发行流通量0.034%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (HANXBIO-B) disclosed a Next Day Disclosure Return dated 13 July 2026, confirming an on-market repurchase of 45,700 H-shares on the Hong Kong Stock Exchange.\nThe transaction, executed on 13 July 2026 under the company’s existing buyback mandate, was completed at prices ranging from HK$28.48 to HK$30.00 per share, with a volume-weighted average cost of HK$28.98. Total consideration amounted to HK$1.32 million.\nFollowing the repurchase, the number of issued shares (excluding treasury shares) fell by 0.034% to 134.25 million, while treasury shares rose to 1.97 million. The company’s total issued share capital remained unchanged at 136.22 million shares.\nThe buyback forms part of the mandate approved on 24 June 2026, which authorises the repurchase of up to 13.47 million shares. Cumulative repurchases under this mandate now stand at 446,100 shares, equivalent to 0.33% of the company’s issued share base at the mandate date. A moratorium on new share issues or treasury-share sales is in effect until 12 August 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146338242","isCrawlerRequest":true}